Notable Upgrades: PTC Therapeutics, Inc. (PTCT), Nokia Corporation (NOK), Avanir Pharmaceuticals (AVNR)

Investment analysts at Deutsche Bank (DB) initiated coverage on shares of PTC Therapeutics, Inc. (PTCT) in a note issued to investors on Monday. The firm set a ‘Buy’ rating and a $75.00 price target on the stock. DB’s price target would suggest a potential upside of 129.21% from the stock’s previous close.

PTC Therapeutics, Inc. shares have a T-12 price-to-sales ratio of 30.39. EPS is ($2.69). Currently there are 2 analysts that rate PTCT a ‘Strong Buy’, 4 rate it a ‘Buy’. No analysts rate it a ‘Hold’ or a ‘Sell’. PTCT has a median Wall Street price target of $41.50 with a high target of $60.00.

In the past 52 weeks, shares of South Plainfield, New Jersey-based company have traded between a low of $13.15 and a high of $37.96 and are now at 35.99. Shares are up 68.65% year-over-year and 112.08% year-to-date.

The chart below shows where the equity has traded over the last year, with the 50-day and 200-day moving averages included.

Nokia Corporation (NOK) was upgraded by Oppenheimer to an ‘Outperform’ from ‘Perform’ rating in a research note issued on Monday. The firm cited the company’s management’s operational track record and capital program/tax assets as one of the reasons for the upgrade. Price target was set at $12/share, implying 40.02% expected return from the stock’s current price.

Nokia shares recently gained $0.21 to $8.57. In the past 52 weeks, shares of Espoo, Finland-based company have traded between a low of $6.22 and a high of $8.61. Shares are up 34.17% year-over-year and 6.04% year-to-date.

The chart below shows where the equity has traded over the last year, with the 50-day and 200-day moving averages included.

Analysts at Piper Jaffray raised their price target on shares of Avanir Pharmaceuticals, Inc. (AVNR) to $17 from $13 in a research report issued to clients on Monday.

AVNR shares recently spiked $4.13, or 61.21%, to $10.80 following announcement of positive results from the company’s Phase II clinical trial for treatment of agitation in patients with Alzheimer’s disease.

The stock is up more than 59.76% year-over-year and has gained roughly 223% year-to-date. In the past 52 weeks, shares of the Aliso Viejo, California-company have traded between a low of $2.62 and a high of $11.38.

Avanir Pharmaceuticals, Inc., which closed Friday at $6.74, has a total market cap of $1.89 billion.

The chart below shows where the equity has traded over the last year, with the 50-day and 200-day moving averages included.

Be the first to comment

Leave a Reply

Your email address will not be published.


*